Please login to the form below

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

AZ gets US approval for Veltassa rival Lokelma

AZ gets US approval for Veltassa rival Lokelma. But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to

Latest news

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
AZ finally gets EU nod for Veltassa rival Lokelma

AZ finally gets EU nod for Veltassa rival Lokelma. And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for
Vifor wins European approval for Veltassa

Vifor wins European approval for Veltassa. European Commission approves the drug to treat hyperkalaemia. ... The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening
FDA turns down AZ's ZS-9 once again on manufacturing issues

The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming
AZ nears EU approval for hyperkalaemia drug Lokelma

AZ nears EU approval for hyperkalaemia drug Lokelma. CHMP adopts positive opinion for the potassium-binding treatment. ... Hyperkalaemia is commonly associated with chronic heart failure and chronic kidney disease, and carries risk of potentially fatal

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

for the treatment of hyperkalaemia.
Deal Watch November 2015

Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
Pharma deals during October 2013

Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Associate Scientific Director: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director or Senior Account Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager: Negotiable

Medical Writers Required - Hertfordshire: Competitive

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Graduate Scientific Editor: DOE

Healthcare PR Senior Account Manager: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Sudler London - Senior Medical Writer: Competitive

Account Manager- 4 days per week or full-time: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Systematic Review Lead- London: Negotiable

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer: Salary is DOE

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....